Home


Login
July 3, 2009
A new path to hope

Brainsgate is a medical device company committed to developing a novel treatment modality, electrical SPG stimulation. This platform technology has been shown to increase blood flow to the brain and as a result has broad potential for treating central nervous system disorders. BrainsGate is currently focusing on:

1. Improve the outcome of patients suffering from ischemic stroke, in a 24 hour window after onset of symptoms.

2. Enable drug delivery into the central nervous system, overcoming the blood-brain barrier, and opening a window for addressing currently untreatable CNS diseases.


Focus: ISS
BrainsGate's product for increasing BBB permeability and improving ischemic stroke outcome read more
Focus: Stroke
The leading cause of adult long-term disability and the third leading cause of death read more
June 16, 2009
BioMed 2009
BrainsGate attends the BioMed 2009 in Tel Aviv > full story
September 25, 2008
BrainsGate launches ImpACT-24
ImpACT-24 is a randomized, sham-controlled, double blind study to test the safety and efficacy of BrainsGate's ISS for treatment of acute ischemic stroke victims in a 24 hour window > full story